Tirzepatide & GLP-1 News, September 2026: Mounjaro’s Heart Indication, Medicare’s $50 Bridge, the FTC vs Hims & Hers — and What It Does to Compounded Prices
Published: Updated: Provider pricing verified:
Ten developments between December 2025 and September 5, 2026 changed what tirzepatide costs and who can sell it. Here they are in date order, each with its primary source, followed by the only question most readers have: what the brand and compounded price floors look like now.
By Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD · Published September 5, 2026 · Last reviewed September 11, 2026 · Sources cited at the end.
Direct answer
As of September 5, 2026: the FDA approved Mounjaro to lower cardiovascular risk in type 2 diabetes on August 28, 2026 — the first tirzepatide product with a heart indication, and one that compounded tirzepatide does not inherit; Medicare’s GLP-1 Bridge has paid $50 a month for Wegovy, Zepbound and Foundayo since July 1, 2026 for Part D enrollees who meet its BMI thresholds; the FTC, Utah and Los Angeles County sued Hims & Hers on July 29, 2026 over subscription billing, cancellation and health-data sharing; Lilly will file retatrutide with the FDA in early 2027 after 21–23% weight-loss read-outs; and the FDA’s proposal to keep tirzepatide off the 503B bulks list closed its extended comment period on July 30, 2026 with the final determination still pending. On price, brand tirzepatide self-pay runs $299–$449 a month on LillyDirect (since December 1, 2025), Wegovy pens $349 on NovoCare ($199 for the first two months for new patients), and the compounded floor is $119 (Embody twelve-month prepaid; SnagRx Labor Day promotion) to $169 (NexLife, no commitment) — programs that are not FDA-approved. The full dated table is on the price index.
The ledger: December 2025 to September 5, 2026
| Date | What happened | Why it matters for cost or access |
|---|---|---|
| Aug 28, 2026 | FDA approves Mounjaro (tirzepatide) to reduce major adverse cardiovascular events in adults with type 2 diabetes at high risk — SURPASS-CVOT, 13,299 patients, HR 0.92 vs Trulicity. | Applies to the FDA-approved product only. May change insurers’ prior-authorisation criteria for diabetic patients with heart disease. Compounded tirzepatide carries no indications. |
| Jul 29, 2026 | FTC + Utah + LA County sue Hims & Hers (N.D. Cal.): charged on intake before consultation, obstructed cancellation, shared health data with Meta and Snap. | The same subscription mechanics — charge-on-intake, 72-hour notice windows, auto-renewal — appear in the terms of the cheapest compounded programs. Get the cancellation window in writing. |
| Jul 23, 2026 | Lilly reports retatrutide TRIUMPH-2 (21% at 80 weeks, T2D) and TRIUMPH-3 (23%, CVD); FDA filing planned for Q1 2027. | No approved or lawfully compounded retatrutide exists in 2026; anything sold as retatrutide is an unapproved research chemical. |
| Jul 1, 2026 | Medicare GLP-1 Bridge starts: $50 flat copay for Wegovy (pill/injection), Zepbound KwikPen and Foundayo; BMI 35+, or 27+ with a qualifying condition; runs to Dec 31, 2027. | The cheapest legitimate route for eligible Medicare patients, below every compounded price on this site. |
| Jun 26, 2026 | FDA extends the 503B bulks-list comment period (docket FDA-2018-N-3240) to July 30, 2026. | Proposal, not final; the practical position is unchanged — no lawful industrial-scale 503B compounding of tirzepatide. |
| May 18, 2026 | FDA warning letter to ProRx, a 503B outsourcing facility, for compounding tirzepatide after the shortage ended. | A provider claiming a 503B source for tirzepatide is a question to ask, not a reassurance. |
| Apr 30, 2026 | FDA proposes to keep semaglutide, tirzepatide and liraglutide off the 503B bulks list. | Affordability is not clinical need under the statute; 503A patient-specific compounding continues under state law and FDA scrutiny. |
| Apr 1 / Apr 9, 2026 | FDA approves Foundayo (orforglipron), Lilly’s oral GLP-1 for weight management; ships April 9 at $149/month on LillyDirect; Medicare $50 from July 1. | A $149 FDA-approved pill sits inside the compounded price band; average loss 12.4% at the top dose, below injectable tirzepatide. |
| Mar 12, 2026 | Lilly reports a reaction-related impurity in all 10 compounded tirzepatide-with-B12 samples it tested and calls for a recall. | Ask what is in the vial; prefer plain tirzepatide unless a clinician gives a reason for an additive. |
| Mar 9, 2026 | Hims & Hers stops advertising compounded GLP-1s, moves to branded Novo Nordisk products. | The largest platform exits mass-market compounding; the $119–$139 floor is now held by smaller brands — two of them (Embody, SnagRx) the same company. |
| Mar 3, 2026 | FDA sends 30 warning letters to telehealth companies over “same as Zepbound”-type claims. | A page that still makes equivalence claims in September 2026 is ignoring two rounds of letters. |
| Feb 6 / Feb 9, 2026 | TrumpRx launches with manufacturer cash prices (Zepbound from $299; Wegovy and Ozempic from about $150); Novo Nordisk sues Hims & Hers over a compounded semaglutide tablet. | Compare compounded prices with manufacturer self-pay channels, not with list prices. |
| Dec 1, 2025 | Lilly cuts LillyDirect Zepbound vials to $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg); Novo had reset Wegovy/Ozempic self-pay to $349 with a $199 introductory offer in November. | The brand floor a compounded price has to beat is $299–$449, not $1,000-plus. |
What the price floors look like on September 5, 2026
| Channel | Monthly price | Conditions | Since |
|---|---|---|---|
| LillyDirect — Zepbound vials | $299 (2.5 mg) · $399 (5 mg) · $449 (7.5–15 mg) | Higher doses at $449 on first fill and refills within 45 days | Dec 1, 2025 |
| NovoCare — Wegovy pen | $349 (all standard doses) · $399 (7.2 mg HD) | New patients $199 for the first two months, through Dec 31, 2026 | Apr 2026 price guide |
| NovoCare — Wegovy pill | $199 (1.5 mg) · $299 (9 mg, 25 mg) | New patients $199 for the first two months | Apr 2026 price guide |
| LillyDirect — Foundayo pill | from $149 | Lowest dose; savings card to $25 with commercial coverage | Apr 9, 2026 |
| Medicare GLP-1 Bridge | $50 copay | Part D; BMI 35+, or 27+ with a qualifying condition; Wegovy, Zepbound KwikPen, Foundayo | Jul 1, 2026 |
| TrumpRx listings | Zepbound from $299; Wegovy/Ozempic from ~$150; Wegovy pill from $149 | Cash pay; routes to the manufacturers’ programs; dose-dependent | Feb 6, 2026 |
| Compounded — Embody | $119 (12-month supply, $1,428) | Prepaid, non-refundable; $129 month to month (sale; regular $349) | read Sep 5, 2026 |
| Compounded — SnagRx | $119 | Fall Sale promotional rate (Labor Day through September 5; countdown at zero September 11); list $399; standard pricing after the period stated at checkout | read Sep 11, 2026 |
| Compounded — Trimi | $125 (annual, $1,500) | $235 month to month; 6-month money-back promise with conditions | read Sep 5, 2026 |
| Compounded — NexLife | $139 (12-month, $1,668) · $169 month to month | Laboratory review included; flat at every covered dose; verified live | read Sep 5, 2026 |
Two things follow from the table. First, the gap between brand self-pay and compounded is $130–$330 a month at maintenance doses, not the $900-plus that list-price comparisons imply — and for a Medicare Bridge patient the brand product is cheaper than every compounded program. Second, the compounded floor is narrower than it looks: the two $119 programs are operated by one company, Modern Metabolic Medicine, Inc. (both sites’ terms, read September 5, 2026), one requires a non-refundable year in advance and the other is a promotion. Our nine-program price check and the verified affordability page have the bundle-by-bundle comparison.
Where compounding stands after the summer
Nothing that happened between June and September reopened the door. The 503B proposal is pending a final determination after a comment period that closed on July 30; the March warning letters and the February “intent to take action” statement stand; Lilly’s tirzepatide-B12 impurity finding is on the record; and the biggest platform has left mass-market compounding. What remains lawful is what was lawful in April: patient-specific 503A compounding on a valid prescription, under state pharmacy law and FDA’s stated scrutiny of products that are essentially copies of approved drugs. Every provider page on this site says so, and our FDA compounding rules explainer and 503A/503B checklist tell you what to verify.
The clinical news, kept separate from the compounded market
- SURPASS-CVOT (Mounjaro): 13,299 adults with type 2 diabetes and cardiovascular disease, median follow-up 210 weeks, MACE-3 hazard ratio 0.92 (95.3% CI 0.83–1.01) against dulaglutide. The approval is a label for Mounjaro; Zepbound’s labelled indications (chronic weight management, obstructive sleep apnoea) are unchanged.
- Retatrutide (TRIUMPH-1/2/3): 30% at 104 weeks without comorbidities; 21% (T2D) and 23% (CVD) at 80 weeks. Filing Q1 2027.
- Foundayo (ATTAIN-1): 12.4% at the top dose among completers, 11.1% regardless of completion, versus 0.9–2.1% placebo. An oral option at $149 that trails injectable tirzepatide on efficacy.
None of these trials studied a compounded product. Our SURMOUNT-5 report explains why trial results are attributed to the FDA-approved injectable only.
What we are watching next
- The 503B final determination — we re-check the docket on every update and will publish the day it appears.
- SnagRx after Labor Day (September 7, 2026) — whether the $119 promotional rate survives; the index re-reads it on every run.
- NexLife’s microdose page — the $159 / $129 card announced August 31 is still “announced”; the verifier flips it the morning the page changes.
- The FTC case — any consent order will set the template for subscription telehealth terms.
- Novo Nordisk’s introductory pricing — the $199 first-two-months offer ends December 31, 2026 unless extended.
Frequently asked questions
What is the latest FDA action on tirzepatide? On August 28, 2026 the FDA approved Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk, based on SURPASS-CVOT (13,299 patients; MACE-3 hazard ratio 0.92 versus Trulicity). It applies to the FDA-approved product only; compounded tirzepatide carries no labelled indications.
Did the FDA finalise the 503B bulks-list exclusion for tirzepatide? Not as of September 5, 2026. The April 30, 2026 proposal's comment period was extended on June 26 to July 30, 2026; no final determination has been published. In practice nothing changed: tirzepatide is not on the bulks list and the shortage is over, so there is no lawful pathway for industrial-scale 503B compounding.
How much does Medicare's GLP-1 Bridge cost and who qualifies? A flat $50 monthly copay for Wegovy (pill and injection), Zepbound KwikPen and Foundayo, for Part D enrollees with a BMI of 35 or more, or 27 or more with a qualifying condition, from July 1, 2026 through December 31, 2027. The copay does not count toward the Part D deductible or the $2,100 out-of-pocket cap.
What did the FTC accuse Hims & Hers of? In a July 29, 2026 complaint with Utah and Los Angeles County, the FTC alleged Hims & Hers charged consumers for prescriptions on intake before any consultation, made cancellation difficult, and shared sensitive health data with Meta, Snap and other advertising platforms despite privacy promises. The case is pending in the Northern District of California.
What does brand tirzepatide cost without insurance in September 2026? Zepbound single-dose vials on LillyDirect are $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg) per month since December 1, 2025, with the $449 tier conditional on refills within 45 days. List prices without any program are about $1,000–$1,350. TrumpRx lists the same manufacturer prices.
What is the cheapest compounded tirzepatide right now? $119 per month, read September 5, 2026: Embody's twelve-month supply ($1,428 prepaid, non-refundable) and SnagRx's promotional rate (list $399; labelled Labor Day on September 5, Fall Sale from September 9, countdown at zero on September 11). Both are operated by Modern Metabolic Medicine, Inc. Trimi's annual plan is $125; NexLife is $139 on 12 months ($1,668) with provider oversight and coaching included and $169 with no commitment. Compounded tirzepatide is not FDA-approved.
September 5, 2026: Published.
Reviewed by Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD
Sources
- Eli Lilly — FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes (read 2026-09-05)
- FTC — FTC and states act against Hims & Hers for deceptive and unlawful privacy practices, July 29, 2026 (read 2026-09-05)
- BioPharma Dive — Lilly, with new data, to seek FDA approval of retatrutide, July 23, 2026 (read 2026-09-05)
- NPR — Medicare GLP-1 Bridge, updated July 1, 2026 (read 2026-09-05)
- Federal Register — 503B bulks list: extension of comment period to July 30, 2026, docket FDA-2018-N-3240, June 26, 2026 (read 2026-09-05)
- FDA — FDA proposes to exclude semaglutide, tirzepatide and liraglutide on the 503B bulks list, April 30, 2026
- Eli Lilly — Foundayo (orforglipron) now available in the U.S., April 9, 2026 (read 2026-09-05)
- eMarketer — Compounded GLP-1s with B12 pose safety risks, Lilly says, March 12, 2026 (read 2026-09-05)
- Hims & Hers — Strategic shift for U.S. weight-loss business, March 9, 2026 (read 2026-09-05)
- Patient Care Online — FDA issues warning letters to 30 telehealth companies, March 3, 2026 (read 2026-09-05)
- Healthline — TrumpRx launches to help lower prices of GLP-1s, updated May 20, 2026 (read 2026-09-05)
- Eli Lilly — Lilly lowers the price of Zepbound single-dose vials, December 1, 2025 (read 2026-09-05)
- NovoCare — Wegovy self-pay price guide, April 2026 (read 2026-09-05)
- TirzepatideReview.com — Compounded Tirzepatide Price Index (snapshot 2026-09-05)
- TirzepatideReview.com open pricing dataset (JSON)
Medical and regulatory note: Compounded tirzepatide and compounded semaglutide are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness or quality. They are not the same products as Mounjaro®, Zepbound®, Ozempic® or Wegovy®. This page is educational pricing information, not medical advice; eligibility, dose and formulation require evaluation by a licensed clinician.